Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first­in­patient trials suggests an alternative NOAEL­based method can be safe while reducing time to the recommended phase 2 dose.

Jessen, Bart A; Cornwell, Paul; Redmond, Sean; Visalli, Thomas; Lemper, Marie; Bunch, Todd; Hart, Timothy

Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule firstinpatient trials suggests an alternative NOAELbased method can be safe while reducing time to the recommended phase 2 dose.

Jessen, Bart A; Cornwell, Paul; Redmond, Sean; Visalli, Thomas; Lemper, Marie; Bunch, Todd; Hart, Timothy.

Afiliación

Jessen BA; Pfizer, Drug Safety Research and Development, San Diego, CA, 92121, USA. bart.jessen@pfizer.com.
Cornwell P; Eli Lilly, Nonclinical Safety Assessment, Indianapolis, IN, USA.
Redmond S; Clinical Pharmacology & Safety Sciences, AstraZeneca Pharmaceuticals, Waltham, MA, 02451, USA.
Visalli T; Eisai Inc., Global Nonclinical Regulatory, Nutley, NJ, 07110, USA.
Lemper M; Development Science, UCB, Inc., Cambridge, MA, 02140, USA.
Bunch T; Nonclinical Safety Evaluation, Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Hart T; GlaxoSmithKline, IVIVT, Collegeville, PA, 19426, USA.

Cancer Chemother Pharmacol ; 2023 Sep 29.

Article en En | MEDLINE | ID: mdl-37773538

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Chemother Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google